Redeye comments on Freemelt’s new order from UKAEA, which deepens Freemelt’s position within the fus...
Tallinna Sadam's y/y decline in total cargo volumes ended in Q1 after persisting for nine quarters.
Redeye endorses Optomed and AEYE Health’s FDA (510k) clearance of Aurora AEYE.
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM...
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time t...
The company writes down EUR 6m receivable which will have a corresponding negative impact on the EBI...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Sales -10% vs. ABGSCe, but EBIT in line at SEK 0m New customer signings in NW&FT and GC&MP to grow s...
Loihde’s Q1 was a pleasant surprise, as we had expected a softer start to the year.
Suominen reports Q1 results on May 7. We see earnings recovering throughout this year towards a norm...
Kraftigt stigande bruttomarginal Nettoomsättningen ökade med 185% till 31,0 mkr (10,9).
Solteq’s Q1 results were slightly weaker than expected and revenue declined slightly y/y in comparab...
Aktieanalytiker Mathias Carlson intervjuar VD Torbjörn Saxmo efter publicerad Q1-rapport.
Net sales have declined for the last four quarters on a q/q basis but this trend could come to an en...
- Q1e: -2% organic growth, adj. EBITA +12% y-o-y - We cut adj.
- Slowdown in Q2 before acceleration occurs in H2'24 - 23% adj.
- Quarterly miss brings down CEPS 2024e by -4% - Awaiting news on Polish acquisition agenda - Share ...
- Excellent cost control behind beat - Market conditions still challenging - Positive update on cost...
Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 29 april att Bolaget har signerat e...
Softer Q1 than expected, but with solid progress for Private We cut '24e-'26e EBIT by 22-6% on lower...
